Phase I trial of lestaurtinib for children with refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium study

@article{Minturn2011PhaseIT,
  title={Phase I trial of lestaurtinib for children with refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium study},
  author={Jane E. Minturn and Audrey E. Evans and Judith G Villablanca and Gregory Anthony Yanik and Julie Park and Suzanne Shusterman and Susan Groshen and Edward T. Hellriegel and Debra M Bensen-Kennedy and Katherine K. Matthay and Garrett M. Brodeur and John M. Maris},
  journal={Cancer Chemotherapy and Pharmacology},
  year={2011},
  volume={68},
  pages={1057-1065}
}
TrkB acts as an oncogenic kinase in a subset of human neuroblastomas. Lestaurtinib, a multi-kinase inhibitor with potent activity against Trk kinases, has demonstrated activity in preclinical models of neuroblastoma. Patients with refractory high-risk neuroblastoma received lestaurtinib twice daily for 5 days out of seven in 28-day cycles, starting at 70% of the adult recommended Phase 2 dose. Lestaurtinib dose was escalated using a 3 + 3 design. Pharmacokinetics and plasma phospho-TrkB… CONTINUE READING
BETA
Highly Cited
This paper has 63 citations. REVIEW CITATIONS

Citations

Publications citing this paper.
SHOWING 1-10 OF 33 CITATIONS, ESTIMATED 52% COVERAGE

63 Citations

051015'12'14'16'18
Citations per Year
Semantic Scholar estimates that this publication has 63 citations based on the available data.

See our FAQ for additional information.

References

Publications referenced by this paper.
SHOWING 1-10 OF 25 REFERENCES

Similar Papers

Loading similar papers…